Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
2
TRAW Quote, Financials, Valuation and Earnings
Last price:
$1.25
Seasonality move
:
-2.86%
Day range:
$1.39 - $2.20
52-week range:
$0.97 - $19.44
Dividend yield:
0%
P/E ratio:
0.06x
P/S ratio:
3.14x
P/B ratio:
2.46x
Volume:
4.5M
Avg. volume:
593.7K
1-year change:
-72.39%
Market cap:
$11.2M
Revenue:
$226K
EPS (TTM):
$24.08
Analysts' Opinion
-
Consensus RatingTraws Pharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.00, Traws Pharma, Inc. has an estimated upside of 471.43% from its current price of $1.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing -471.43% downside risk from its current price of $1.40.
Fair Value
-
According to the consensus of 1 analyst, Traws Pharma, Inc. has 471.43% upside to fair value with a price target of $8.00 per share.
TRAW vs. S&P 500
-
Over the past 5 trading days, Traws Pharma, Inc. has underperformed the S&P 500 by -42.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Traws Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Traws Pharma, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Traws Pharma, Inc. reported revenues of --.
Earnings Growth
-
Traws Pharma, Inc. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Traws Pharma, Inc. reported earnings per share of -$0.34.
Enterprise value:
4.8M
EV / Invested capital:
1.05x
Price / LTM sales:
3.14x
EV / EBIT:
--
EV / Revenue:
1.68x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.8M
Return On Assets:
576.05%
Net Income Margin (TTM):
-61696.04%
Return On Equity:
-124.39%
Return On Invested Capital:
-124.39%
Operating Margin:
-45.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $226K | $226K | $2.8M | $57K | -- | |
| Gross Profit | $210K | $212K | $2.8M | $55K | -$15K | |
| Operating Income | -$21.6M | -$24.1M | -$40.2M | -$8.5M | -$4.1M | |
| EBITDA | -$21.6M | -$24.1M | -$40.2M | -$8.5M | -$4M | |
| Diluted EPS | -$24.07 | -$134.02 | $24.08 | -$1.49 | -$0.34 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $59.9M | $43.8M | $27M | $8.9M | $9.6M | |
| Total Assets | $60M | $43.8M | $27M | $8.9M | $12.4M | |
| Current Liabilities | $7M | $7.3M | $9.7M | $8.3M | $7.9M | |
| Total Liabilities | $10.3M | $10.4M | $12.5M | $11M | $7.9M | |
| Total Equity | $49.7M | $33.4M | $14.5M | -$2M | $4.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17.4M | -$30.2M | -$19.5M | -$11.5M | -$4M | |
| Cash From Investing | -$14K | -$3.6M | -$2.6M | -- | -$2.6M | |
| Cash From Financing | -- | $14M | $23M | -- | -$62K | |
| Free Cash Flow | -$17.4M | -$30.2M | -$19.5M | -$11.5M | -$4M | |
TRAW
Sector
Market Cap
$11.2M
$28.1M
Price % of 52-Week High
7.2%
51.42%
Dividend Yield
0%
0%
Shareholder Yield
-174.51%
-1.45%
1-Year Price Total Return
-72.39%
-19.74%
Beta (5-Year)
1.745
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.20
200-day SMA
Sell
Level
$1.93
Bollinger Bands (100)
Sell
Level
1.58 - 2.54
Chaikin Money Flow
Sell
Level
-4.4M
20-day SMA
Sell
Level
$2.29
Relative Strength Index (RSI14)
Sell
Level
31.23
ADX Line
Sell
Level
7.14
Williams %R
Buy
Level
-99.2701
50-day SMA
Sell
Level
$2.42
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-4.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-41.934)
Sell
CA Score
(Annual)
Level (-14.1157)
Sell
Beneish M-Score
(Annual)
Level (81.969)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (22.57)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
Stock Forecast FAQ
In the current month, TRAW has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRAW average analyst price target in the past 3 months is $8.00.
-
Where Will Traws Pharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Traws Pharma, Inc. share price will rise to $8.00 per share over the next 12 months.
-
What Do Analysts Say About Traws Pharma, Inc.?
Analysts are divided on their view about Traws Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Traws Pharma, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Traws Pharma, Inc.'s Price Target?
The price target for Traws Pharma, Inc. over the next 1-year time period is forecast to be $8.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRAW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Traws Pharma, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of TRAW?
You can purchase shares of Traws Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Traws Pharma, Inc. shares.
-
What Is The Traws Pharma, Inc. Share Price Today?
Traws Pharma, Inc. was last trading at $1.25 per share. This represents the most recent stock quote for Traws Pharma, Inc.. Yesterday, Traws Pharma, Inc. closed at $1.40 per share.
-
How To Buy Traws Pharma, Inc. Stock Online?
In order to purchase Traws Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TRAW Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TRAW
Sector
P/E ratio
0.06x
23.98x
PEG ratio
0.00x
-0.01x
P/B ratio
2.46x
1.81x
Price / LTM sales
3.14x
1.60x
Growth Metrics
TRAW
Sector
Revenue growth
-100%
4.62%
Earnings growth
76.9%
10.88%
Revenue (5-year growth)
-36.47%
6.5%
Earnings forecast
--
-$0.20
Profitability
TRAW
Sector
Profitability FY 2024
$214K
$3.6M
Return on invested capital
-124.39%
-31.84%
Return on assets
576.05%
-27.89%
Return on equity
-124.39%
-37.47%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
18
Estimated Next Earnings Date
Mar
19
Balance Sheet
TRAW
Sector
Total cash
$6.4M
$26.6M
Short term investments
--
$25.7M
Total assets
$25M
$78M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 37x
Alerts
Sell
46
BE alert for Dec 18
Bloom Energy Corp. [BE] is up 4.27% over the past day.
Sell
44
STRL alert for Dec 18
Sterling Infrastructure, Inc. [STRL] is up 6.62% over the past day.
Sell
39
SOXL alert for Dec 18
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 7.28% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
